PEPTIDES

Generic Peptides

Our Generic Peptides

Octreotide Acetate
Cat #
Introduction Octreotide, sold under the brand name Sandostatin among others, is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979 by the chemist Wilfried Bauer, and binds predominantly to the somatostatin receptors SSTR2 and SSTR5. It was approved for use in the United States in 1988.
Sequence C49H66N10O10S2
MW 1019.25
Reference 1. "Sandostatin Lar Depot- octreotide acetate kit". DailyMed. 11 April 2019. Archived from the original on 24 March 2021. Retrieved 16 February 2020.

2. "Bynfezia Pen- octreotide acetate injection". DailyMed. 19 February 2020. Archived from the original on 19 September 2022. Retrieved 19 April 2021.

3. Hofland, L. J.; Lamberts, S. W. (January 1996). "Somatostatin receptors and disease: role of receptor subtypes". Bailliere's Clinical Endocrinology and Metabolism. 10 (1): 163–176. doi:10.1016/s0950-351x(96)80362-4. hdl:1765/60433. ISSN 0950-351X. PMID 8734455. Archived from the original on 11 August 2022. Retrieved 9 March 2021.

4. Octreotide Monograph

5. Moattari AR, Cho K, Vinik AI (1990). "Somatostatin analogue in treatment of coexisting glucagonoma and pancreatic pseudocyst: dissociation of responses". Surgery. 108 (3): 581–7. PMID 2168587.
Fields of application
Synonyms
Structure
목록